17 known cases. View patent page →
Federal Circuit appeal from the PTAB IPR decision on U.S. 8,589,182. The court affirmed, holding the FDA Advisory Committee materials were a publicly accessible printed publication and proper prior art; the decision disposed of the family patents together.
Second D.N.J. suit by Jazz against Roxane Laboratories involving the '106 patent. It was closed.
Jazz sued Par Pharmaceutical in D.N.J. involving the '106 patent. The case was closed and later settled, with Amneal/Par authorized generic rights from July 1, 2023.
Jazz sued Ranbaxy entities in D.N.J. involving the '106 patent. The case was closed and later settled.
Jazz sued Watson Laboratories in D.N.J. involving the '106 patent. The case was closed and later settled.
Jazz sued Wockhardt entities in D.N.J. involving the '106 patent. The case was closed, settled, and Wockhardt was later terminated from the related IPR.
Jazz Pharmaceuticals, Inc. et al. sued Lupin entities in D.N.J. involving the '106 patent. The case was closed and later settled June 12, 2018 per Hagens Berman complaint; docket noted termination Jan. 15, 2016 per L. Civ. R. 11.2 certification.
Jazz Pharmaceuticals Ireland Ltd. sued Ascent Pharmaceuticals in D.N.J. involving the '106 patent. The case was closed.
A closed E.D.N.Y. action in the Jazz/JPI Commercial/Orphan Medical line involving the '106 patent per Unified Patents. The defendant was not identified in retrieved sources.
Jazz entities sued Mallinckrodt Inc. in D.N.J. involving the '106 patent. The case was closed and later settled.
Roxane Laboratories et al. filed a covered business method review against Jazz on the '106 patent. The PTAB did not institute the review.
Amneal Pharmaceuticals LLC, joined by Par Pharmaceutical and Wockhardt Bio AG, filed an IPR against Jazz on the '106 patent. The PTAB held all claims unpatentable as obvious; rehearing was denied.
Wockhardt Bio AG filed an IPR against Jazz on the '106 patent, joined with IPR2015-00546. The proceeding was terminated as to Wockhardt after settlement.
Antitrust action by Blue Cross and Blue Shield Association against Jazz in N.D. Cal. It cites the '106 patent among patents at issue and was terminated July 15, 2020.
Antitrust action by United HealthCare Services against Jazz in D. Minn. It cites the '106 patent among patents at issue and was terminated April 15, 2021.
Class action antitrust suit by UFCW Local 1500 Welfare Fund against Jazz and others in E.D.N.Y. It alleges the '106 patent was improperly listed in the Orange Book and invalid.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.